HC Wainwright & Co. Reiterates Buy on Cyclo Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Cyclo Therapeutics (NASDAQ:CYTH) and maintained a price target of $3.
August 16, 2024 | 4:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Cyclo Therapeutics and maintained a price target of $3.
The reiteration of a Buy rating and the maintenance of a $3 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100